Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: A systematic literature review and network meta-analysis

Immune checkpoint inhibitors and targeted therapies are approved for adjuvant treatment of patients with resected melanoma; however, they have not been compared in randomized controlled trials (RCTs). We compared the efficacy and safety of adjuvant nivolumab with other approved treatments using available evidence from RCTs in a Bayesian network meta-analysis (NMA).